Optimized pro-active management of anemia by Epoetin α in pre-operative chemotherapy for primary breast cancer

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 777-785

  Warm, Mathias ^a   Kates, Ronald ^b   Dick, Michelle ^a   Thomas, Anke ^c   Mallmann, Peter ^a   Hoopmann, Markus ^a   Harbeck, Nadia ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b REK Consulting   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anemia; Breast cancer; Epoetin ; Pre operative chemotherapy

Indexed keywords

BLOOD CLOTTING FACTOR; EPIRUBICIN; HEMOGLOBIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PEROPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SURVIVAL TIME; TISSUE OXYGENATION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; EPIRUBICIN; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL;

EID: 64849100158     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000284     Document Type: Article

References (28)

1. Fisher B, Bryant J, Wolmark N, Marmounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
2. Calais G, Berger C and Descamps P: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74: 1283-1288, 1994.
3. Forrest AP, Levack PA and Chetty U: A human tumour model. Lancet 2: 840-842, 1986.
4. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, Luini A, Andreola S, Rilke F, Raselli R, et al: Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222: 612-618, 1995.
5. Von Bauerfeind I: Operative Therapie des Mammakarzinoms: Brusterhaltung. In: Diagnostik und Therapie des Mammakarzinoms-State of the Art. W. Zuckerschwerdt Verlag (ed.), München, pp241-248, 2004.
6. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997.
7. Rice GC, Ling V and Schimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 84: 9261-9264, 1987.
8. Sanna K and Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58: 258-262, 1994.
9. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
10. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
11. Ellis LM and Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 32A: A2451-A2460, 1996.
12. Young SD, Marshall RS and Hill RP: Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 85: 9533-9537, 1988.
13. Heiss MM, Mempel W, Delanoff C, Mempel M, Jauch KW and Schildberg FW: Clinical effects of blood transfusion-associated immune modulation on outcome of tumor surgery. Infusionsther Transfusions med 20 (Suppl 2): 25-29, 1993.
14. Dietzfelbinger H and Woitinas F: Substitution and protective therapy with blood components. Med Klin 74: 680-685, 1979.
15. Kelleher DK, Mattheinsen U, Thews O and Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56: 4728-4734, 1996.
16. Dammacco F, Castoldi G and Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113: 172-179, 2001.
17. Rizzo JD, Lichtin AE, Woolf SH, et al: American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
18. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L and Soubeyran P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216, 2004.
19. Rosenbaum PR and Rubin DB: Reducing bias in observational studies using sub-classification on the propensity score. J Amer Statist Assoc 79: 516-524, 1994.
20. Von Koch F, Kahlert S and Untch M: Die Bedeutung der Anämie für Therapie und Prognose des Mammakarzinoms. In: Diagnostik und Therapie des Mammakarzinoms-State of the Art. W. Zuckerschwerdt Verlag (ed.), München, pp368-381, 2004.
21. Wilhelm R, Kovacs G, Heinrichsohn D, Galalae R and Kimmig B: Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level. Strahlenther Onkol 174: 128-132, 1998.
22. Chatani M, Matayoshi Y, Masaki N and Inoue T: High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation. T Strahlenther Onkol 173: 379-384, 1997.
23. Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O'Brien M, Van Belle S and Vaupel P: Cancerrelated anemia: biological findings, clinical implications and impact on quality of life. Oncology 68 (Suppl 1): 12-21, 2005.
24. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr and Coia LR: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13: 2077-2283, 1995.
25. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW and Fritz E: Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319-2329, 1995.
26. Knight K, Wade S and Calducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (Suppl 7): A11-A26, 2004.
27. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G and Beguin Y: Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81: 434-441, 1996.
28. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M and Rosso R: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715-2721, 1997.